c/o exertional sob, renal cardiac normal , suggest management
Reading File
Let me analyze the CXR and search for relevant management guidance simultaneously.
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
I now have sufficient information to provide a comprehensive answer. Let me fetch the IPF CXR reference image for comparison.
Loading Image
CXR Interpretation — T. Janardhan Rao, 85Y M
Patient: 85-year-old male | Exertional SOB | Renal and cardiac workup normal
Radiographic Findings
The CXR shows:
- Bilateral basal-predominant reticular opacities — coarse, lace-like shadowing at both lung bases
- Relative upper lobe sparing — upper zones appear relatively clear
- Reduced lung volumes — a hallmark of restrictive parenchymal disease
- No cardiomegaly, no pleural effusion, no consolidation
- Heart size normal (consistent with "cardiac normal")
Reference image (textbook IPF): 
The pattern is strongly consistent with Idiopathic Pulmonary Fibrosis (IPF) / Usual Interstitial Pneumonia (UIP) pattern.
Suggested Management
1. Confirm Diagnosis First
| Investigation | Purpose |
|---|---|
| HRCT chest (high priority) | Mandatory for ILD characterization — look for honeycombing, traction bronchiectasis, subpleural basilar reticulation (UIP pattern) |
| PFTs (spirometry + DLCO) | Establishes severity — restrictive defect with reduced DLCO |
| 6-minute walk test | Baseline exercise capacity + O₂ desaturation |
| Autoimmune screen (ANA, RF, anti-CCP, Scl-70, Jo-1) | Rule out CTD-ILD (treatable with immunosuppression) |
| Occupational/drug history | Rule out hypersensitivity pneumonitis or drug-induced ILD |
| BAL ± surgical lung biopsy (VATS) | If HRCT is indeterminate; VATS preferred over TBBx |
HRCT showing a definite UIP pattern in the right clinical context is sufficient to diagnose IPF without biopsy.
2. Antifibrotic Therapy (Disease-Modifying)
For IPF with mild-to-moderate functional impairment (FVC ≥50%, DLCO ≥30%):
| Drug | Dose | Mechanism | Effect |
|---|---|---|---|
| Pirfenidone | Up to 2403 mg/day (3 divided doses) | Anti-inflammatory, anti-fibrotic, anti-oxidant | Slows FVC decline, reduces respiratory hospitalizations; pooled data suggest survival benefit |
| Nintedanib | 150 mg orally twice daily | Tyrosine kinase inhibitor (PDGFR, VEGFR, FGFR) | Reduces FVC decline by similar magnitude to pirfenidone; comparable mortality benefit |
Both agents are first-line — choice is based on tolerability (pirfenidone: photosensitivity/GI; nintedanib: diarrhea/hepatotoxicity) and cost.
Agents to AVOID in IPF:
- Oral corticosteroids (monotherapy or with azathioprine/cyclophosphamide — harmful)
- N-acetylcysteine, sildenafil, bosentan, macitentan, warfarin — no benefit or harmful
3. Symptomatic & Supportive Care
| Intervention | Indication/Notes |
|---|---|
| Supplemental O₂ | If SpO₂ <88% at rest or on exertion — improves exercise tolerance |
| Pulmonary rehabilitation | Improves exercise capacity and quality of life |
| Vaccinations | Influenza, pneumococcus, herpes zoster — all appropriate |
| Treat infections promptly | Respiratory tract infections accelerate decline |
| Screen & treat pulmonary hypertension | If present: inhaled treprostinil 72 µg QID can improve exercise capacity; avoid endothelin receptor antagonists (ambrisentan is harmful in IPF) |
| GI/GERD management | PPI/H2 blocker for symptomatic reflux — no proven survival benefit |
4. Acute Exacerbation (if it occurs)
Empirical IV corticosteroids:
- Methylprednisolone 1g IV pulse × 3 days → then hydrocortisone 125 mg q6h × 3–5 days
- Rule out infection, PE, aspiration before attributing to AE-IPF
5. Advanced Considerations (Given Age 85)
| Issue | Comment |
|---|---|
| Lung transplantation | Age >70 is a relative contraindication; not likely suitable here |
| Palliative care | Should be introduced early — dyspnea management (low-dose opioids), goals of care discussion |
| Opioids for refractory dyspnea | Low-dose oral morphine is appropriate for palliation |
Summary Flowchart
Exertional SOB + bilateral basal reticulation on CXR
→ Cardiac/renal excluded ✓
→ HRCT chest (definite UIP = IPF diagnosis)
→ PFTs + DLCO → grade severity
→ Autoimmune screen → CTD-ILD ruled out
→ Start antifibrotic: Pirfenidone OR Nintedanib
→ O₂, pulmonary rehab, vaccines, treat comorbidities
→ Palliative care discussion (age 85)
Sources: Goldman-Cecil Medicine, p. 190–200; Washington Manual of Medical Therapeutics, p. 7187–7219
This is a shared conversation. Sign in to Orris to start your own chat.